

Collaborative Framework for Delivering on Ways That Digital Technologies Can Help to Optimize New Parkinson's Treatment Trials



Diane Stephenson¹, Jesse M. Cedarbaum², Klaus Romero¹, Polly Dawkins³, Sara Garvey³, Mark Frasier⁴, Alyssa Reimer⁴, Lauren Bataille^{4*}, James Beck⁵, Karlin Schroeder⁵, Beth Vernaleo⁵, David Dexter⁶, Jill Gallagher⁶, Joy Duffen⁷, Helen Matthews⁷, Steve Ford⁶

¹Critical Path Institute, Tucson, AZ, ²Biogen, Cambridge, MA, ³Davis Phinney Foundation, Boulder, CO, ⁴Michael J Fox Foundation, NYC, NY, ⁵Parkinson's Foundation, New York, ⁶Parkinson's UK, London, UK, ⁷The Cure Parkinson's Trust, London, UK



PARKINSON'S^{UK}
CHANGE ATTITUDES. FIND A CURE. JOIN US.

Background and Objectives

Development of effective therapies for Parkinson's is a high risk and costly endeavor. Recently, a focus on data collected using new digital technologies has been introduced to improve the assessment of day-to-day experience of people living with Parkinson's. Worldwide collaborative initiatives are in place to take advantage of mobile sensors and devices as new tools to inform drug development decision-making.

The Critical Path for Parkinson's (CPP) consortium, a public-private partnership sponsored by Critical Path Institute, Parkinson's UK and industry aims to advance innovative new tools to optimize clinical trials. (1)



Objective: To present CPP's pre-competitive collaborative worldwide network and describe how all stakeholders are working together to advance the utility of digital technologies for use in Parkinson's trials.

Critical Path for Parkinson's consortium




What is Important to you?

TODAY:
How do we measure what is important to you?

Scores, scales, markers, neurological examination etc. (things that your doctors use today)



TOMORROW:
How can we improve the way we measure what is important to you?




TECHNOLOGY:




E. Ray Dorsey (3) *Arora et al., 2018 (4)*

- "Participants emphasized the difficulty of living with...progression of symptoms. Many described living with daily motor symptoms which included **bradykinesia, dyskinesia, tremor and dystonia**. ...participants also highlighted **sleep disturbances, cognitive impairment, fatigue, and constipation**."
- "...patients were asked to identify up to three symptoms that have the greatest impact on daily life. **Motor symptoms, impaired balance and coordination, cognitive impairment, and sleep disturbances** received the highest number of responses."
- "Several participants highlighted the **cognitive effects** of Parkinson's disease on their day to day activities."
- "Comments regarding **fatigue** resonated with meeting participants."
- "Several participants commented that they experienced significant **depression and anxiety**."
- "Participants shared that their symptoms, particularly **motor symptoms, impaired balance, and cognitive impairment**, had significant impacts on their ability to perform at their job."
- "Many participants commented that the **lack of energy, anxiety, and motor symptoms** led to social isolation."

(2) FDA VOP report Parkinson's Disease; Public Meeting: September 22, 2015 Report Date: April 2016, CDER

Critical Path for Parkinson's Consortium



Conclusions

The information gathered from CPP's assessment of the use of digital technology in Parkinson's studies will apply learnings from other consortium initiatives to develop novel tools to improve Parkinson's clinical trials. A robust collaboration between all stakeholders around the world centered on data standards and data sharing is key for success in the future.

References

- (1) Stephenson et al., 2015; J. Parkinson's Dis 5(3): 581–594.
- (2) FDA 2016 Parkinson's Disease Voice of the Patient Report [Internet]. U.S. Food and Drug Administration; 2016 Apr.
- (3) E. Ray Dorsey, 2018 unpublished
- (4) Arora et al., 91(16): Neurology 19, e1528–e1538.

Acknowledgments: The Critical Path Institute's Critical Path for Parkinson's (CPP) Consortium is funded by Parkinson's UK and the following industry members: AbbVie, Biogen, Denali, GSK, H. Lundbeck A/S, Merck Sharp and Dohme, F. Hoffmann La Roche, Sanofi Genzyme, IXICO, Takeda and UCB. We also acknowledge additional CPP member organizations, including Cure Parkinson's Trust, Davis Phinney Foundation, Michael J. Fox Foundation, Newcastle University, Parkinson's Foundation, Radboud University, University of Cambridge, University of Glasgow, University of Oxford, NINDS, FDA, and EMA. The authors acknowledge Ira Shoulson, Michele Hu, Maurizio Facheris, Ray Dorsey and Arthur Roach. [*author current affiliation: Novartis]